Other equities research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Intellipharmaceutics International from a hold rating to a buy rating and set a $2.00 price target for the company in a report on Tuesday, September 13th. Brean Capital restated a buy rating and issued a $8.00 price target on shares of Intellipharmaceutics International in a report on Tuesday, July 5th.
Shares of Intellipharmaceutics International (NASDAQ:IPCI) traded up 6.20% during midday trading on Thursday, reaching $2.38. 370,868 shares of the company traded hands. Intellipharmaceutics International has a 1-year low of $1.41 and a 1-year high of $3.19. The company has a 50 day moving average price of $1.93 and a 200 day moving average price of $1.83. The company’s market capitalization is $68.42 million.
Intellipharmaceutics International (NASDAQ:IPCI) last posted its quarterly earnings results on Wednesday, July 13th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. Intellipharmaceutics International had a negative net margin of 325.20% and a negative return on equity of 832.00%. On average, analysts expect that Intellipharmaceutics International will post ($0.28) earnings per share for the current year.
An institutional investor recently bought a new position in Intellipharmaceutics International stock. Atria Investments LLC acquired a new stake in Intellipharmaceutics International Inc. (NASDAQ:IPCI) during the second quarter, according to its most recent filing with the SEC. The institutional investor acquired 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned about 0.27% of Intellipharmaceutics International at the end of the most recent quarter. Institutional investors and hedge funds own 1.30% of the company’s stock.
Intellipharmaceutics International Company Profile
Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.